Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Outline of Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02600455

Enrollment

505

Registered

2015-11-09

Start date

2013-09-30

Completion date

2016-06-30

Last updated

2017-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.

Interventions

DRUGOrencia

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are beginning to receive the treatment with ORENCIA Subcutaneous Injection 125mg Syringe 1mL under the approved indications, dosage, and administration

Design outcomes

Primary

Measure	Time frame
Safety measured by number of Adverse events and laboratory abnormalities associated with adverse events	24 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026